Suppr超能文献

玻璃体内注射阿柏西普作为伊尔斯病所致视网膜新生血管和黄斑水肿的挽救治疗

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease.

作者信息

Hsia Ning-Yi, Lin Chun-Ju, Lai Chun-Ting, Bair Henry, Chang Cheng-Hsien, Lin Jane-Ming, Tsai Yi-Yu

机构信息

Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.

School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

出版信息

Case Rep Ophthalmol Med. 2021 Feb 11;2021:8887362. doi: 10.1155/2021/8887362. eCollection 2021.

Abstract

We report the rescue effect of intravitreal aflibercept injections on retinal neovascularization and macular edema due to Eales disease. Case 1 was a 36-year-old female. Intravitreal aflibercept was administered as rescue therapy after persistent retinal neovascularization following retinal photocoagulation, periocular triamcinolone, and intravitreal ranibizumab injection. Retinal neovascularization initially regressed, but recurred after 5 months along with macular edema. Two more intravitreal aflibercept injections were given, and retinal neovascularization with macular edema regressed. Her vision improved to 20/25 and remained stable after 43 months. Case 2 was a 27-year-old female. Intravitreal aflibercept was administered after persistent retinal neovascularization and macular edema following periocular triamcinolone injection. The macular edema initially subsided but recurred after 3 months. Intravitreal aflibercept injections were then administered once every three months to maintain her vision 20/20. The patient has been followed up for 28 months. Intravitreal aflibercept was effective as a rescue therapy in the treatment of Eales disease to regress retinal neovascularization, though repeated injections were necessary in cases of recurrence.

摘要

我们报告了玻璃体内注射阿柏西普对伊尔斯病所致视网膜新生血管形成和黄斑水肿的挽救作用。病例1为一名36岁女性。在视网膜光凝、球周注射曲安奈德和玻璃体内注射雷珠单抗后仍持续存在视网膜新生血管形成,遂将玻璃体内注射阿柏西普作为挽救治疗。视网膜新生血管形成最初消退,但5个月后复发并伴有黄斑水肿。又进行了两次玻璃体内注射阿柏西普,视网膜新生血管形成伴黄斑水肿消退。她的视力提高到20/25,43个月后保持稳定。病例2为一名27岁女性。在球周注射曲安奈德后出现持续的视网膜新生血管形成和黄斑水肿,遂给予玻璃体内注射阿柏西普。黄斑水肿最初消退,但3个月后复发。随后每三个月进行一次玻璃体内注射阿柏西普以维持其20/20的视力。该患者已随访28个月。玻璃体内注射阿柏西普作为伊尔斯病的挽救治疗可有效消退视网膜新生血管形成,尽管复发时需要重复注射。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/043f/7892226/ba67c67e7ff1/CRIOPM2021-8887362.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验